Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
Anti-Mullerian hormone
Biologic drugs
Disease-modifying antirheumatic drug
Fertility
Juvenile idiopathic arthritis
Ovarian reserve
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
30 Aug 2023
30 Aug 2023
Historique:
received:
25
04
2023
accepted:
18
08
2023
revised:
07
08
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
aheadofprint
Résumé
The aim of the study is to assess the effect of juvenile idiopathic arthritis (JIA) and biologic disease-modifying anti-rheumatic drugs (bDMARDs) on ovarian reserve in children. A cross-sectional study was performed from March 2021 to March 2022 and included 81 patients with JIA and 49 healthy children. Serum anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol levels were analyzed using electrochemiluminescence methods. The mean of current age (13.5 ± 3.2 vs. 14.4 ± 2.4 years), height standard deviation score (SDS) (- 0.35 ± 1.18 vs. - 0.44 ± 0.94), body mass index SDS (0.12 ± 1.33 vs. 0.25 ± 1.28), and the median weight SDS (- 0.13 (- 2.27-3.23) vs. - 0.52 (- 3.4-3.3)) were similar in JIA patients and controls (p > 0.05). Patients with JIA were divided into two groups according to their treatment regimens: treated with methotrexate (MTX) (biologic naive) (n = 32) and treated with MTX plus bDMARDs (n = 49). No significant differences were detected between the 3 groups regarding menarche age, menstrual cycle length, and flow duration (for all p > 0.05). The median serum concentration of AMH was 2.94 (1.12-7.88) ng/ml in the control group, 3.02 (0.36-8.54) ng/ml in the biologic naïve group, and 3.01 (0.99-8.26) ng/ml in the MTX plus bDMARD group. There were no significant differences between 3 groups according to serum AMH, FSH, LH, and estradiol levels (p > 0.05). Biologic DMARDs are reassuring in terms of ovarian reserve in girls with JIA and demonstrate that AMH is unaffected by treatment. Prospective studies with larger sample sizes are needed to confirm our findings and to evaluate the impact on the future fertility of patients. Key Points • Although biologic disease-modifying anti-rheumatic drugs (bDMARDs) are being game-changing treatment options in juvenile idiopathic arthritis, their effect on fertility and ovarian reserve is one of the most discussed issues. • In addition to treatment used, autoimmune diseases might also have a negative effect on fertility. • In this cross-sectional study, we found that anti-Mullerian hormone level of patients who were on bDMARDs, patients who were on methotrexate, and healthy controls were similar. • Our results suggest that bDMARDs are reassuring in terms of ovarian reserve in girls with JIA and demonstrate that AMH is unaffected by treatment.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
The aim of the study is to assess the effect of juvenile idiopathic arthritis (JIA) and biologic disease-modifying anti-rheumatic drugs (bDMARDs) on ovarian reserve in children.
MATERIALS AND METHODS
METHODS
A cross-sectional study was performed from March 2021 to March 2022 and included 81 patients with JIA and 49 healthy children. Serum anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol levels were analyzed using electrochemiluminescence methods.
RESULTS
RESULTS
The mean of current age (13.5 ± 3.2 vs. 14.4 ± 2.4 years), height standard deviation score (SDS) (- 0.35 ± 1.18 vs. - 0.44 ± 0.94), body mass index SDS (0.12 ± 1.33 vs. 0.25 ± 1.28), and the median weight SDS (- 0.13 (- 2.27-3.23) vs. - 0.52 (- 3.4-3.3)) were similar in JIA patients and controls (p > 0.05). Patients with JIA were divided into two groups according to their treatment regimens: treated with methotrexate (MTX) (biologic naive) (n = 32) and treated with MTX plus bDMARDs (n = 49). No significant differences were detected between the 3 groups regarding menarche age, menstrual cycle length, and flow duration (for all p > 0.05). The median serum concentration of AMH was 2.94 (1.12-7.88) ng/ml in the control group, 3.02 (0.36-8.54) ng/ml in the biologic naïve group, and 3.01 (0.99-8.26) ng/ml in the MTX plus bDMARD group. There were no significant differences between 3 groups according to serum AMH, FSH, LH, and estradiol levels (p > 0.05).
CONCLUSION
CONCLUSIONS
Biologic DMARDs are reassuring in terms of ovarian reserve in girls with JIA and demonstrate that AMH is unaffected by treatment. Prospective studies with larger sample sizes are needed to confirm our findings and to evaluate the impact on the future fertility of patients. Key Points • Although biologic disease-modifying anti-rheumatic drugs (bDMARDs) are being game-changing treatment options in juvenile idiopathic arthritis, their effect on fertility and ovarian reserve is one of the most discussed issues. • In addition to treatment used, autoimmune diseases might also have a negative effect on fertility. • In this cross-sectional study, we found that anti-Mullerian hormone level of patients who were on bDMARDs, patients who were on methotrexate, and healthy controls were similar. • Our results suggest that bDMARDs are reassuring in terms of ovarian reserve in girls with JIA and demonstrate that AMH is unaffected by treatment.
Identifiants
pubmed: 37646858
doi: 10.1007/s10067-023-06747-w
pii: 10.1007/s10067-023-06747-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Turkish Pediatric Association
ID : 09.04.2021/04
Informations de copyright
© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Adrovic A, Yildiz M, Köker O, Şahin S, Barut K, Kasapçopur Ö (2021) Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review. Arch Rheumatol 36(1):146–157
pubmed: 34046584
Barut K, Adrovic A, Şahin S, Kasapçopur Ö (2017) Juvenile idiopathic arthritis. Balkan Med J 34(2):90–101. https://doi.org/10.4274/balkanmedj.2017.0111
doi: 10.4274/balkanmedj.2017.0111
pubmed: 28418334
pmcid: 5394305
Koker O, Sahin S, Adrovic A, Yildiz M, Barut K, Gulle B, Eker Omeroglu R, Kasapcopur O (2020) A controversial topic in juvenile idiopathic arthritis: association between biologic agents and malignancy. Int J Rheum Dis 23(9):1210–1218. https://doi.org/10.1111/1756-185x.13906
doi: 10.1111/1756-185x.13906
pubmed: 32691529
Barut K, Şahin S, Adrovic A, Köşker M, Kılıç Ö, Camcıoğlu Y, Çokuğraş H, Akçakaya N, Sözeri B, Kasapçopur Ö (2018) Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy. Turk J Med Sci 48(6):1109–1114. https://doi.org/10.3906/sag-1710-190
doi: 10.3906/sag-1710-190
pubmed: 30541234
Brouwer J, Dolhain R, Hazes JMW, Visser JA, Laven JSE (2019) Reduced ovarian function in female rheumatoid arthritis patients trying to conceive. ACR Open Rheumatol 1(5):327–335. https://doi.org/10.1002/acr2.11043
doi: 10.1002/acr2.11043
pubmed: 31777809
pmcid: 6857972
Silva CA, Bonfa E, Østensen M (2010) Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care Res 62(12):1682–1690. https://doi.org/10.1002/acr.20323
doi: 10.1002/acr.20323
Valdeyron C, Soubrier M, Pereira B, Constantin A, Morel J, Gaudin P, Combe B, Gremeau AS, Dejou-Bouillet L, Pouly JL, Sapin V, Oris C, Brugnon F (2021) Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. Rheumatology 60(4):1863–1870. https://doi.org/10.1093/rheumatology/keaa535
doi: 10.1093/rheumatology/keaa535
pubmed: 33147613
Bhide P, Pundir J, Homburg R, Acharya G (2019) Biomarkers of ovarian reserve in childhood and adolescence: a systematic review. Acta Obstet Gynecol Scand 98(5):563–572. https://doi.org/10.1111/aogs.13574
doi: 10.1111/aogs.13574
pubmed: 30758847
Coelho Neto MA, Ludwin A, Borrell A, Benacerraf B, Dewailly D, da Silva CF, Condous G, Alcazar JL, Jokubkiene L, Guerriero S, Van den Bosch T, Martins WP (2018) Counting ovarian antral follicles by ultrasound: a practical guide. Ultrasound Obstet Gynecol 51(1):10–20. https://doi.org/10.1002/uog.18945
doi: 10.1002/uog.18945
pubmed: 29080259
Jeong HR, Lee HJ, Shim YS, Kang MJ, Yang S, Hwang IT (2020) Inhibin B as a screening tool for early detection and treatment monitoring of central precocious puberty. Gynecol Endocrinol 36(9):768–771. https://doi.org/10.1080/09513590.2020.1718642
doi: 10.1080/09513590.2020.1718642
pubmed: 32162574
Welt CK, McNicholl DJ, Taylor AE, Hall JE (1999) Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 84(1):105–111. https://doi.org/10.1210/jcem.84.1.5381
doi: 10.1210/jcem.84.1.5381
pubmed: 9920069
Practice Committee of the American Society for Reproductive Medicine (2020) Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 114(6):1151–1157. https://doi.org/10.1016/j.fertnstert.2020.09.134
doi: 10.1016/j.fertnstert.2020.09.134
Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WH, Anderson RA (2014) The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 20(3):370–385. https://doi.org/10.1093/humupd/dmt062
doi: 10.1093/humupd/dmt062
pubmed: 24430863
Xu H, Zhang M, Zhang H, Alpadi K, Wang L, Li R, Qiao J (2021) Clinical applications of serum anti-Müllerian hormone measurements in both males and females: an update. Innovation 2(1):100091. https://doi.org/10.1016/j.xinn.2021.100091
doi: 10.1016/j.xinn.2021.100091
pubmed: 34557745
pmcid: 8454570
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton. J Rheumatol, 2001 31(2):390–392
Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F (2017) A comprehensive online calculator for pediatric endocrinologists: ÇEDD Çözüm/TPEDS Metrics. J Clin Res Pediatr Endocrinol 9(2):182–184. https://doi.org/10.4274/jcrpe.4526
doi: 10.4274/jcrpe.4526
pubmed: 28443820
pmcid: 5463294
Cohen J, Chabbert-Buffet N, Darai E (2015) Diminished ovarian reserve, premature ovarian failure, poor ovarian responder–a plea for universal definitions. J Assist Reprod Genet 32(12):1709–1712. https://doi.org/10.1007/s10815-015-0595-y
doi: 10.1007/s10815-015-0595-y
pubmed: 26463876
pmcid: 4681731
Lopez-Corbeto M, Martínez-Mateu S, Pluma A, Ferrer R, López-Lasanta M, De Agustín JJ, Barceló M, Julià A, Marsal S (2021) The ovarian reserve as measured by the anti-Müllerian hormone is not diminished in patients with rheumatoid arthritis compared to the healthy population. Clin Exp Rheumatol 39(2):337–343. https://doi.org/10.55563/clinexprheumatol/73txen
doi: 10.55563/clinexprheumatol/73txen
pubmed: 32896242
Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ (2013) Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res 65(9):1534–1538. https://doi.org/10.1002/acr.22013
doi: 10.1002/acr.22013
Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, Igney-Oertel A, Lawrenz B, Henes JC (2015) Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet’s disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology 54(9):1709–1712. https://doi.org/10.1093/rheumatology/kev124
doi: 10.1093/rheumatology/kev124
pubmed: 25957439
Eudy AM, McDaniel G, Hurd WW, Clowse MEB (2019) Fertility and ovarian reserve among women with rheumatoid arthritis. J Rheumatol 46(5):455–459. https://doi.org/10.3899/jrheum.180176
doi: 10.3899/jrheum.180176
pubmed: 30442826
de Araujo DB, Yamakami LY, Aikawa NE, Bonfá E, Viana VS, Pasoto SG, Pereira RM, Serafin PC, Borba EF, Silva CA (2014) Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate? Scand J Rheumatol 43(6):503–511. https://doi.org/10.3109/03009742.2014.908237
doi: 10.3109/03009742.2014.908237
pubmed: 24881927
Ferreira GRV, Tomioka RB, Aikawa NE, Leon EP, Maciel GAR, Serafini PC, Baracat EC, Goldenstein-Schainberg C, Pereira RMR, Bonfá E, Silva CA (2019) Ovarian reserve in young juvenile idiopathic arthritis patients. Mod Rheumatol 29(3):447–451. https://doi.org/10.1080/14397595.2018.1465646
doi: 10.1080/14397595.2018.1465646
pubmed: 29652213
Alexander VM, Ashley-Martin J, Riley JK, Cooper AR, Ratts VS, Jungheim ES (2021) Association between arthritis treatments and ovarian reserve: a prospective study. Reprod Biomed Online 42(6):1203–1210. https://doi.org/10.1016/j.rbmo.2021.03.018
doi: 10.1016/j.rbmo.2021.03.018
pubmed: 33931373
pmcid: 8884072
Brouwer J, Hazes JM, Laven JS, Dolhain RJ (2015) Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 74(10):1836–1841. https://doi.org/10.1136/annrheumdis-2014-205383
doi: 10.1136/annrheumdis-2014-205383
pubmed: 24833784
McLaren JF, Burney RO, Milki AA, Westphal LM, Dahan MH, Lathi RB (2009) Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation. Fertil Steril 92(2):515–519. https://doi.org/10.1016/j.fertnstert.2008.07.009
doi: 10.1016/j.fertnstert.2008.07.009
pubmed: 18829004
Isojima S, Miura Y, Saito M, Yajima N, Miwa Y, Kasama T (2019) Serum anti-Müllerian hormone levels in women with rheumatoid arthritis during tumor necrosis factor-α inhibitor treatment: exploratory research. Obstet Med 12(4):186–189. https://doi.org/10.1177/1753495x18820471
doi: 10.1177/1753495x18820471
pubmed: 31853259
pmcid: 6909303
Eken MK, Ersoy GS, Kaygusuz EI, Devranoğlu B, Takır M, Çilingir ÖT, Çevik Ö (2019) Etanercept protects ovarian reserve against ischemia/reperfusion injury in a rat model. Arch Med Sci 15(4):1104–1112. https://doi.org/10.5114/aoms.2017.72406
doi: 10.5114/aoms.2017.72406
pubmed: 31360205
pmcid: 6657239
Kaplan S, Türk A (2020) Adalimumab increases follicle reserve and follicle development in rat ovary: the effect of adalimumab on ovarian reserve. Cureus 12(10):e11230. https://doi.org/10.7759/cureus.11230
doi: 10.7759/cureus.11230
pubmed: 33269158
pmcid: 7704188
Zhao XY, Li ZB, Yuan HJ, Han X, Wu JS, Feng XY, Zhang M, Tan JH (2020) Restraint stress and elevation of corticotrophin-releasing hormone in female mice impair oocyte competence through activation of the tumour necrosis factor α (TNF-α) system. Reprod Fertil Dev 32(9):862–872. https://doi.org/10.1071/rd20002
doi: 10.1071/rd20002
pubmed: 32527376
Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60(1):8–16. https://doi.org/10.1111/j.1600-0897.2008.00585.x
doi: 10.1111/j.1600-0897.2008.00585.x
pubmed: 18422811